Acurx Pharmaceuticals Inc (ACXP)

Jan 7, 2025, 5:00 PM EST - 10 days ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 11 days ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 11 days ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 5 weeks ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 5 weeks ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 2 months ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 2 months ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 2 months ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 11:43 AM EST - 2 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 2 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 10:07 AM EDT - 3 months ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 7:00 AM EDT - 3 months ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 3 months ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 11, 2024, 10:50 AM EDT - 3 months ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

ZAPP

Sep 26, 2024, 7:00 AM EDT - 4 months ago

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 24, 2024, 7:00 AM EDT - 4 months ago

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Aug 26, 2024, 7:00 AM EDT - 5 months ago

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 10:20 AM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:01 AM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

Jul 17, 2024, 7:00 AM EDT - 6 months ago

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Jul 16, 2024, 7:00 AM EDT - 6 months ago

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Jul 15, 2024, 7:00 AM EDT - 6 months ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

May 15, 2024, 1:14 PM EDT - 8 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

May 15, 2024, 9:00 AM EDT - 8 months ago

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

May 15, 2024, 7:00 AM EDT - 8 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 7:00 AM EDT - 9 months ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Apr 25, 2024, 10:12 AM EDT - 9 months ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Apr 23, 2024, 10:57 AM EDT - 9 months ago

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

Mar 21, 2024, 7:01 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

Mar 18, 2024, 11:19 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 7:01 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Mar 4, 2024, 7:01 AM EST - 11 months ago

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

Feb 27, 2024, 7:01 AM EST - 11 months ago

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

Jan 29, 2024, 7:00 AM EST - 1 year ago

Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Jan 23, 2024, 7:01 AM EST - 1 year ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024

Jan 22, 2024, 12:04 PM EST - 1 year ago

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Jan 17, 2024, 7:01 AM EST - 1 year ago

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Jan 3, 2024, 8:00 AM EST - 1 year ago

Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 7:01 AM EST - 1 year ago

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

Nov 14, 2023, 4:28 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 7:01 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

Nov 6, 2023, 9:00 AM EST - 1 year ago

Acurx Undervalued And Set For Potential M&A With Next-Gen C. Diff Treatment

Nov 2, 2023, 7:01 AM EDT - 1 year ago

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

Oct 25, 2023, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update

Oct 19, 2023, 7:01 AM EDT - 1 year ago

Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

Oct 2, 2023, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

Sep 12, 2023, 7:01 AM EDT - 1 year ago

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Aug 22, 2023, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023